Session » Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster III

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2977

A Meta-Analysis of Phosphodiesterase 5 Inhibitors for the Treatment of Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2989

A Romanian Version of the University of Californa at Los Angeles Scleroderma Clinical Trial Consortium Gastrointestinal Tract (UCLA SCTC GIT 2.0) Instrument

9:00AM-11:00AM: Abstract Number: 2976

Ambrisentan Dose Migration over 3 Years in Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension (CTD-PAH)

9:00AM-11:00AM: Abstract Number: 2987

An EULAR Study Group Pilot Study on Reliability of Simple� Capillaroscopic Definitions to Describe Capillary Morphology in Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2990

Assessment of NT-Pro BNP As a Potential Marker for Pulmonary Hypertension in Systemic Sclerosis: Data from a Large, Prospective and Unselected Patient Cohort

9:00AM-11:00AM: Abstract Number: 2980

Assessment of Sublingual Frenulum Perfusion in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2982

Blood Perfusion in Different Skin Areas of Hands in Primary Raynaud’s Phenomenon and Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2972

Cardiopulmonary Exercise Testing in Patients with Systemic Sclerosis: Unexplored Mechanisms of Dyspnea

9:00AM-11:00AM: Abstract Number: 2963

Correlations Between Microvasculature Changes and Angiogenic Factors in Systemic Sclerosis – Data from a Single Center Registry

9:00AM-11:00AM: Abstract Number: 2962

Efficacy of Mycophenolate As a Maintenance Therapy Following the Administration of Cyclophosphamide in the Treatment of Interstitial Lung Disease Associated with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2991

Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2973

Exercise Intolerance Evaluated By Invasive Cardiopulmonary Exercise Testing in Connective Tissue Disease: Beyond Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 2992

Identification of a New Set of Activity Criteria for Systemic Sclerosis. Preliminary Report

9:00AM-11:00AM: Abstract Number: 2975

Induced Sputum Analysis in Systemic Sclerosis Patients

9:00AM-11:00AM: Abstract Number: 2964

Influences of Various Factors on Survival of Patients Treated with Pulmonary Arterial Hypertension-Specific Drugs Combination Therapy in Patients with Connective Tissue Diseases

9:00AM-11:00AM: Abstract Number: 2974

Insulin Resistance Is Associated with the Digital Ulcer in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2968

Interrater Reliability of Nailfold Capillaroscopy in Systemic Sclerosis Using Widefield Microscopy

9:00AM-11:00AM: Abstract Number: 2979

Laser Speckled Imaging and Videomicroscopy Assessment of Sublingual Perfusion in Systemic Sclerosis and Healthy Controls

9:00AM-11:00AM: Abstract Number: 2978

Longitudinal Assessment of Gastrointestinal Symptoms in the Prospective Registry of Early Systemic Sclerosis Cohort

9:00AM-11:00AM: Abstract Number: 2981

Measurement of Tissue Damage in Scleroderma Using Digital Mammographic Xrays: A Proof of Concept Study

9:00AM-11:00AM: Abstract Number: 2965

Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?

9:00AM-11:00AM: Abstract Number: 2967

Musculoskeletal Involvement in SSc Correlates with Poor Short Form 36 and SSc Health Assessment Questionnaire Scores As Well As Lower TNF-Alpha Gene Expression in PBMCs

9:00AM-11:00AM: Abstract Number: 2985

Mycophenolate Mofetil (MMF) Use in Systemic Sclerosis (SSc) Patients with a Designation of Elevated Systolic Pulmonary Artery Pressure (sPAP): Forced Vital Capacity (FVC), Outcomes and Survival from the European Scleroderma Trials and Research (EUSTAR) Database

9:00AM-11:00AM: Abstract Number: 2988

Novel Use of Musculoskeletal Ultrasound (MSUS) to Measure Ulcers in the Skin of Systemic Sclerosis (SSc) Patients.

9:00AM-11:00AM: Abstract Number: 2970

Primary Care Assessment of Capillaroscopy Abnormalities in Patients with Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 2966

Pulmonary Involvement in Systemic Sclerosis at Initial Presentation: A Single Center Experience

9:00AM-11:00AM: Abstract Number: 2971

Raynaud Phenomenon Subjects with Abnormal Capillary Dilations Show a Risk Threshold Diameter Value for the Transition to the Capillaroscopic Early� Scleroderma Pattern: A Case Control Study

9:00AM-11:00AM: Abstract Number: 2961

Reliability and Validity of the Total Joint Count and Swollen Joint Count in Early Diffuse Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 2984

Scleroderma Bronchoalveolar Lavage Fluid Thrombin Activity: Correlation with Pulmonary Function

9:00AM-11:00AM: Abstract Number: 2993

Serum CXCL4 Increase in Patients with Undifferentiated Connective Tissue Disease at Risk for Systemic Sclerosis Is Associated with Anti-Scl70 Antibodies and ICAM-1, a Marker of Endothelial Activation

9:00AM-11:00AM: Abstract Number: 2960

Sodium Thiosulfate in Calcinosis

9:00AM-11:00AM: Abstract Number: 2986

Systemic Sclerosis Patients on Intensive Care Unit – Reasons for Admission and Determinants of Outcome

9:00AM-11:00AM: Abstract Number: 2969

X-Ray Diffraction of Spontaneously Draining Calcinosis in Patients with Scleroderma

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].